RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Akero Therapeutics Stock

Akero Therapeutics P/E 2025

Akero Therapeutics P/E

-13.79

Ticker

AKRO

ISIN

US00973Y1082

WKN

A2PLNP

As of Jul 24, 2025, Akero Therapeutics's P/E ratio was -13.79, a 86.1% change from the -7.41 P/E ratio recorded in the previous year.

The Akero Therapeutics P/E history

Akero Therapeutics Aktienanalyse

What does Akero Therapeutics do?

Akero Therapeutics Inc is an advanced biotherapy company focused on the development and commercialization of medications to improve patient health. The company was founded in 2017 by five experienced pharmaceutical experts: Andrew Cheng, Timothy Lu, David D. Kirn, Scott Freeman, and Stuart Lockhart. Akero Therapeutics Inc is headquartered in Belmont, California, USA. The business model of Akero Therapeutics Inc is based on targeted biological therapy aiming to address unmet medical needs in various disease areas. The idea is to reduce the risk of diseases such as diabetes, chronic liver diseases, and metabolic disorders and improve the quality of life for patients through the development of innovative biological agents. Akero Therapeutics is dedicated to combating these diseases with groundbreaking therapeutic approaches. The company offers various divisions including product development, research and development, and commercial. Product development at Akero Therapeutics encompasses the discovery, development, clinical testing, and efficacy assessment of new biological agents. The research division continuously works on identifying new target molecules to develop innovative approaches in disease therapy. The commercial division of Akero Therapeutics is responsible for developing an appropriate marketing strategy to bring the biological agents to market readiness and to patients. One of the most well-known products of Akero Therapeutics is the medication Efruxifermin (EFX). It is a protein molecule developed for the treatment of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease characterized by the accumulation of fat in the liver without the patient consuming alcohol during the day. Fatty liver disease is a growing public health issue and one of the most common liver diseases worldwide. Akero Therapeutics has developed an effective medication, EFX, which effectively reduces liver fat content. Another product currently in the clinical research phase at Akero Therapeutics is AKR-001. It is a medication for the treatment of patients with lipid metabolism disorders, including hypertriglyceridemia and homozygous familial hypercholesterolemia. Lipid metabolism disorders are characterized by high levels of triglycerides and cholesterol in the blood and increase a patient's risk for cardiovascular diseases. In summary, Akero Therapeutics is a clinical biotherapy company dedicated to the development of treatments for various chronic diseases. The company combines innovative research with strong entrepreneurial capabilities to explore, develop, and bring new biological agents to the market for disease therapy. Akero Therapeutics is on track to establish a strong presence in the biopharmaceutical industry and has the potential to improve the lives of millions of patients worldwide. Akero Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Akero Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Akero Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Akero Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Akero Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Akero Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Akero Therapeutics stock

What is the price-to-earnings ratio of Akero Therapeutics?

The price-earnings ratio of Akero Therapeutics is currently -13.79.

How has the price-earnings ratio of Akero Therapeutics changed compared to last year?

The price-to-earnings ratio of Akero Therapeutics has increased by 86.1% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Akero Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Akero Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Akero Therapeutics affect the company?

An increase in the price-earnings ratio of Akero Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Akero Therapeutics affect the company?

A decrease in the price-earnings ratio of Akero Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Akero Therapeutics?

Some factors that influence the price-earnings ratio of Akero Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Akero Therapeutics pay?

Over the past 12 months, Akero Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akero Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Akero Therapeutics?

The current dividend yield of Akero Therapeutics is .

When does Akero Therapeutics pay dividends?

Akero Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akero Therapeutics?

Akero Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Akero Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akero Therapeutics located?

Akero Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akero Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akero Therapeutics from 7/24/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/24/2025.

When did Akero Therapeutics pay the last dividend?

The last dividend was paid out on 7/24/2025.

What was the dividend of Akero Therapeutics in the year 2024?

In the year 2024, Akero Therapeutics distributed 0 USD as dividends.

In which currency does Akero Therapeutics pay out the dividend?

The dividends of Akero Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Akero Therapeutics

Our stock analysis for Akero Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akero Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.